Corbus Q2 Loss Deepens on Higher R&D Spend; Cash Runway into 2028, Key September Catalysts Loom
CRBP sits 27% above its 52-week low of $7.12.
Summary
Corbus Pharmaceuticals posted a wider Q2 loss on higher R&D costs, including a $10M milestone payment. Cash runway extends into 2028. Key September catalysts: TEMPO-1 study start and CANYON-1 obesity data readout.
Key Events · Earnings and Guidance · CRBP
-
Q2 Net Loss Widens
Net loss of $35.0M ($1.81/share) vs $17.7M ($1.44/share) in Q2 2025, driven by a $10M milestone payment for CRB-701 and higher clinical costs.
-
Cash Runway into 2028
Cash, equivalents, and investments of $117.9M as of June 30, 2026, expected to fund operations into 2028 based on current plans.
-
TEMPO-1 Study to Start in September
FDA cleared the registrational TEMPO-1 study (n=250) of CRB-701 in 2L oropharyngeal cancer; enrollment expected to begin in September 2026.
-
CANYON-1 Obesity Data in September
Phase 1b CANYON-1 study of CRB-913 in obesity (n=240) completed last patient visit; topline data readout on track for September 2026.
Analysis · CRBP · Life Sciences
A wider Q2 net loss of $35.0 million reflects a $10 million milestone payment for CRB-701 and increased clinical spending. With $117.9 million in cash at quarter-end, the runway extends into 2028. Two pivotal catalysts are now set for September: the start of the TEMPO-1 registrational study for CRB-701 in oropharyngeal cancer and topline data from the CANYON-1 Phase 1b obesity trial of CRB-913. These events could significantly de-risk the pipeline and reshape the investment thesis.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRBP was trading at $9.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $177.3M. The 52-week trading range was $7.12 to $20.56. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.